A comment on 'Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials'

被引：0
|
作者：
Goldenberg, Ronald M. [1 ,2 ]
机构：
[1] LMC Diabet & Endocrinol, Vaughan, ON, Canada
[2] LMC Diabet & Endocrinol, 1600 Steeles Ave West 5, Vaughan, ON L4K 4M2, Canada
来源：
DIABETES OBESITY & METABOLISM | 2024年 / 26卷 / 07期
关键词：
D O I：
10.1111/dom.15588
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2997 / 2999
页数：3
相关论文
共 50 条
  • [31] Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials
    Dicembrini, Ilaria
    Nreu, Besmir
    Scatena, Alessia
    Andreozzi, Francesco
    Sesti, Giorgio
    Mannucci, Edoardo
    Monami, Matteo
    ACTA DIABETOLOGICA, 2017, 54 (10) : 933 - 941
  • [32] Glucagon-like Peptide-1 Receptor Agonists Versus Insulin Glargine for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Li, Wei-Xin
    Gou, Jian-Feng
    Tian, Jin-Hui
    Yan, Xiang
    Yang, Lin
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2010, 71 (04): : 211 - 238
  • [33] Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials
    Cheng, Liang
    Hu, Yun
    Li, Yun-Yun
    Cao, Xin
    Bai, Ning
    Lu, Ting-Ting
    Li, Guo-Qing
    Li, Na
    Wang, An-Ning
    Mao, Xiao-Ming
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35 (07)
  • [34] Association of Glucagon-like peptide-1 receptor agonists use with fracture risk in type 2 diabetes: A meta-analysis of randomized controlled trials
    Zhang, Yuan
    Chen, Guanhua
    Wang, Weimin
    Yang, Donghui
    Zhu, Dalong
    Jing, Yali
    BONE, 2025, 192
  • [35] Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials
    Monami, Matteo
    Marchionni, Niccolo
    Mannucci, Edoardo
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2009, 160 (06) : 909 - 917
  • [36] Use of glucagon-like peptide-1 receptor agonists and bone fractures: A meta-analysis of randomized clinical trials
    Mabilleau, Guillaume
    Mieczkowska, Aleksandra
    Chappard, Daniel
    JOURNAL OF DIABETES, 2014, 6 (03) : 260 - 266
  • [37] Effects of glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in high-risk type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
    Chen, Xiaomei
    Zhang, Xuge
    Xiang, Xiang
    Fang, Xiang
    Feng, Shenghong
    DIABETOLOGY & METABOLIC SYNDROME, 2024, 16 (01):
  • [38] Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomised controlled trials
    Bray, Jonathan J. H.
    Foster-Davies, Harri
    Salem, Ahmed
    Hoole, Amy L.
    Obaid, Daniel R.
    Halcox, Julian P. J.
    Stephens, Jeffrey W.
    DIABETES OBESITY & METABOLISM, 2021, 23 (08): : 1806 - 1822
  • [39] Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials
    Sijin Wu
    Wenzhao Lu
    Zhongli Chen
    Yan Dai
    Keping Chen
    Shu Zhang
    Diabetology & Metabolic Syndrome, 14
  • [40] Comparative effectiveness of glucagon-like peptide-1 receptor agonists on body composition and anthropometric indices: A protocol for a systematic review and network meta-analysis of randomized controlled trials
    Wachiraphansakul, Nuttaya
    Vongchaiudomchoke, Thanawat
    Manosroi, Worapaka
    Nochaiwong, Surapon
    PLOS ONE, 2024, 19 (02):
12345